News in brief

India’s Cipla to invest £100m in UK R&D

India’s Cipla to invest £100m in UK R&D

Mumbai-based drugmaker Cipla has announced it will invest “up to £100m” ($171m) in drug development in the UK.

The company’s commitment to invest in its UK subsidiary over several years was agreed following a trade visit to India by George Osborne, Chancellor of the Exchequer for the UK.

Cipla said it will fund the launch of “a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as  well as research and development, clinical trials and further expansion internationally and in the UK.

Its decision “shows the UK's international  strength and attractiveness in this sector as well as its growing importance in Cipla’s long term  strategy,” said the company’s Chief Financial Officer, Rajesh Garg. The company was pleased with the UK government’s “proactive support,” he said, and said it viewed the UK as “a key hub in our global footprint.”

A treasury spokesman told in-Pharmatechnologist.com Cipla had not yet established full details about the R&D areas the £100m will be spent. He added, “This is an excellent announcement for us, as it underscores the attraction of the UK as a cutting edge hub able to attract top investment.

Part of the purpose of the visit was to strengthen the two countries’ economic ties, said the spokesman, “which are very strong at the moment.

Related News

Cipla acquires mAb manufacturer Mabpharm

Cipla acquires mAb manufacturer Mabpharm

Cipla buys Indian plants from contractor

Cipla buys Indian plants from contractor

SGS is expanding its testing facilities in Mumbai, India

Indian manufacturing problems spur growth... for testing companies

FDI investment in manufacturing plants in the UK falling

Foreign investment in UK drugmaking down; ABPI tasks ex-GSK exec with reversing trend

Cipla to invest in three new API plants in India

Cipla to invest in three new API plants in India

News from Cipla, Dr Reddy’s and Immunogen – People on the move

News from Cipla, Dr Reddy’s and Immunogen – People on the move

Meda Adds Spacer-Integrated Inhaler with $135m Acquisition

Meda Adds Spacer-Integrated Inhaler with $135m Acquisition

Inside India: A voyage into pharma manufacturing, trial policies

Inside India: A voyage into the subcontinent's pharma manufacturing, clinical trial policies

Excipient industry group IPEC India launches after delays

Excipient industry group IPEC India launches after delays